Latest news

Debiopharm awarded $2.1 million from CARB-X in the fight against a highly resistant nosocomial-pneumonia causing superbug

GenePOC, a subsidiary of Debiopharm Group, reaches an agreement with Meridian Bioscience for the acquisition of their molecular diagnostics business

GenePOC obtains CE marked for its GenePOCTM Carba test

Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in…

GenePOC obtains FDA clearance for its GenePOC™ Strep A test

ACTEON has entered into exclusive negotiations to acquire the Dental Division of VILLA SISTEMI MEDICALI

Debiopharm International SA Initiates a Clinical Trial Phase II study evaluating afabicin in Bone and Joint Infections

Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II study evaluating Debio 1347 in Advanced Solid Tumors harboring an…

Challenge pour la Qualité de vie du patient 2019 : l’appel à projets est ouvert !